Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2108-2113

  Illei, Peter B ^a,b   Rusch, Valerie W ^a   Zakowski, Maureen F ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; GENE PRODUCT; PHOSPHORYLASE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CDKN2A GENE; CELL TYPE; CENTROMERE; CHROMOSOME 9P; CORRELATION ANALYSIS; CYTOGENETICS; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MTAP GENE; PLEURA MESOTHELIOMA; PREVALENCE; PRIORITY JOURNAL; PURINE SYNTHESIS;

ADULT; AGED; FEMALE; GENE DELETION; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 0038515139     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rusch, V. W. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg., 9: 367-372, 1997.
2. Rusch, V. W., Rosenzweig, K., Venkatraman, E., Leon, L., Raben, A., Harrison, L., Bains, M. S., Downey, R. J., and Ginsberg, R. J. A Phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., 122: 788-795, 2001.
3. Zellos, L. S., and Sugarbaker, D. J. Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Huntingt.), 16: 907-913, 2002.
4. Carbone, M., Kratzke, R. A., and Testa, J. R. The pathogenesis of mesothelioma. Semin. Oncol., 29: 2-17, 2002.
5. Lee, W. C., and Testa, J. R. Somatic genetic alterations in human malignant mesothelioma. Int. J. Oncol., 14: 181-188. 1999.
6. Sandberg, A. A., and Bridge, J. A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors, Mesothelioma. Cancer Genet. Cytogenet., 127: 93-110, 2001.
7. Cheng, J. Q., Jhanwar. S. C., Lu, Y. Y., and Testa, J. R. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res., 53: 4761-4763, 1993.
8. Xiao, S., Li, D., Vijg, J., Sugarbaker, D. J., Corson, J. M., and Fletcher, J. A. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene, 11: 511-515, 1995.
9. Prins, J. B., Williamson, K. A., Kamp, M. M., Van Hezik, E. J., Van der Kwast, T. H., Hagemeijer, A., and Versnel, M. A. The gene for the cyclin-dependent-kinase-4 inhibitor. CDKN2A, is preferentially deleted in malignant mesothelioma. Int. J. Cancer, 75: 649-653, 1998.
10. Hirao, T., Bueno, R., Chen, C. J., Gordon, G. J., Heilig, E., and Kelsey, K. T. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis (Lond.), 23: 1127-1130, 2002.
11. Kamb, A., Gruis. N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, I. I. I. R., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash. DC), 264: 436-440, 1994.
12. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
13. Sherr, C. J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol., 2: 731-737, 2001.
14. Stadler, W. M., and Olopade, O. I. The 9p21 region in bladder cancer cell lines: large homozygous deletions inactivate the CDKN2, CDKN2B and MTAP genes. Urol. Res., 24: 239-244, 1996.
15. Zhang, H., Chen, Z. H., and Savarese, T. M. Codeletion of the genes for p161NK4, methylthioadenosine phosphorylase, interferon-α1, interferon-β1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet., 86: 22-28, 1996.
16. Hori, Y., Hori, H., Yamada, Y., Carrera, C. J., Tomonaga, M., Kamihira, S., Carson, D. A., and Nobori, T. The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int. J. Cancer, 75: 51-56, 1998.
17. Kovar, H., Jug, G. Aryee, D. N. T., Zoubek, A., Ambros, P., Gruber, B., Windhager, R., and Gadner, H. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene, 15: 2225-2232, 1997.
18. Illei, P. B., Feiner, H., Symmans, F., Mitnick, J. S., Roses, D. F., and Perle, M. A. Numerical abnormalities of chromosomes 7, 18 and X in precancerous breast disease defined by fluorescent in situ hybridization. Breast J., 4: 252-257, 1998.
19. Garcia-Castellano, J. M., Villanueva, A., Healey, J. H., Sowers, R., Cordon-Cardo, C., Huvos, A., Bertino, J. R., Meyers, P., and Gorlick, R. Methykhioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin. Cancer Res., 8: 782-787, 2002.
20. Perry, A., Anderl, K., Borell, T. J., Kimmel, D. W., Wang, C. H., O'Fallon, J. R., Feuerstein, B. G., Scheithauer, B. W., and Jenkins, R. B. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am. J. Clin. Pathol, 112: 801-809, 1999.
21. Brat, D. J., James, C. D., Jedlicka, A. E., Connolly, D. C., Chang, E., Castellani, R. J., Schmid, M., Schiller, M., Carson, D. A., and Burger, P. C. Molecular genetic alterations in radiation-induced astrocytomas. Am. J. Pathol, 154: 1431-1438, 1999.
22. Dreyling, M. H., Bohlander, S. K., Le Beau, M. M., and Olopade, O. I. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood, 86: 1931-1938, 1995.
23. M'soka, T. J., Nishioka, J., Taga, A., Kato, K., Kawasaki, H., Yamada, Y., Yu, A., Komada, Y., and Nobori, T. Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. Leukemia (Baltimore), 14: 935-940, 2000.
24. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
25. Chen, Z. H., Zhang, H., and Savarese, T. M. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, α- and β-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res., 56: 1083-1090, 1996.
26. Olopade, O. I., Pomykala, H. M., Hagos, F., Sveen, L. W., Espinosa, R., III, Dreyling, M. H., Gursky, S., Stadler, W. M., Le Beau, M. M., and Bohlander, S. K. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc. Natl. Acad. Sci. USA, 92: 6489-6493, 1995.
27. Nobori, T., Takabayashi, K., Tran, P., Orvis, L., Batova, A., Yu, A. L., and Carson, D. A. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc. Natl. Acad. Sci. USA, 93: 6203-6208, 1996.
28. Schmid, M., Malicki, D., Nobori. T., Rosenbach, M. D., Campbell, K., Carson, D. A., and Carrera, C. J. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene, 17: 2669-2675, 1998.
29. Della, R. F., Russo, G., Oliva, A., Mastropietro, S., Mancini, A., Borrelli, A., Casero, R. A., Iolascon, A., and Zappia, V. 5′-Deoxy-5′-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene, 10: 827-833, 1995.
30. Creagan, E. T., Long, H. J., Ahmann, D. L., and Green, S. J. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. Am. J. Clin. Oncol., 7: 543-544, 1984.
31. Morton, R. F., Creagan, E. I., Cullinan, S. A., Mailliard, J. A., Ebbert, L., Veeder. M. H., and Chang, M. Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. J. Clin. Oncol., 5: 1078-1082, 1987.
32. Elson, P. J., Kvols, L. K., Vogl, S. E., Glover, D. J., Hahn, R. G., Trump, D. L., Carbone, P. P., Earle, J. D., and Davis, T. E. Phase II trials of 5-day vinblastine infusion (NSC 49842). L-Alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Investig. New Drugs, 6: 97-103, 1988.
33. Yu, J. Alanosine (UCSD). Curr. Opin. Investig. Drugs, 2: 1623-1630, 2001.
34. Batova, A., Diccianni, M. B., Omura-Minamisawa, M., Yu, J., Carrera, C. J., Bridgeman, L. J., Kung, F. H., Pullen, J., Amylon, M. D., and Yu, A. L. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res., 59: 1492-1497, 1999.
35. Harasawa, H., Yamada, Y., Kudoh, M., Sugahara, K., Soda, H., Hirakata, Y., Sasaki, H., Ikeda, S., Matsuo, T., Tomonaga, M., Nobori, T., and Kamihira, S. Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). Leukemia (Baltimore), 16: 1799-1807, 2002.
36. Yu, J., Batova, A., Shao, L., Carrera, C. J., and Yu, A. L. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies. Clin. Cancer Res., 3: 433-438, 1997.
37. Chen, Z. H., Olopade, O. I., and Savarese, T. M. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP-malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol. Pharmacol., 52: 903-911, 1997.
38. Frizelle, S. P., Rubins, J. B., Zhou, J. X., Curiel, D. T., and Kratzke, R. A. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther., 7: 1421-1425, 2000.
39. Yang, C. T., You, L., Yeh, C. C., Chang, J. W., Zhang, F., McCormick, F., and Jablons, D. M. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. (Bethesda), 92: 636-641, 2000.
40. Yang, C. T., You, L., Uematsu, K., Yeh, C. C., McCormick, F., and Jablons, D. M. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res., 61: 5959-5963, 2001.
41. Illei, P. B., Ladanyi, M., Rusch, V., and Zakowski, M. F. CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer (Cancer Cytopathol) 99: 51-56, 2003.